Embargoed and Restricted Access
Reason: Under embargo until May 2025. After this date a copy can be supplied under Section 51(2) of the Australian Copyright Act 1968 by submitting a document delivery request through your library, or by emailing firstname.lastname@example.org
Elucidating the molecular regulation of the dendritic cell receptor, Clec9A
thesisposted on 2022-05-11, 04:25 authored by NICOLE MICHAEL
Dendritic cells are the immune cells critical in vaccination as they sense danger and initiate immunity. Clec9A is a Dendritic cell receptor that is the target for novel vaccine technologies that enhance immunity to cancers and viruses. Our research identified a novel regulatory pathway for Clec9A. Clec9A interacts with other proteins, namely RNF41, ERLIN1/2 and TMEM59. ERLIN/2 and RNF41 promote the degradation of Clec9A, while TMEM59 enhances the display of Clec9A at the dendritic cell surface potentially to enhance Clec9A-mediated immune responses. These novel pathways may ultimately be exploited to enhance Clec9A-based vaccines and promote immunity to cancer.